Birkenhäger T K, Moleman P
Stichting RBC, Den Haag.
Ned Tijdschr Geneeskd. 1999 May 1;143(18):934-7.
Mirtazapine and venlafaxine are two novel antidepressants which are pharmacologically different from other new anti-depressants. Mirtazapine blocks the presynaptic alpha 2-adrenoreceptors and has a benign safety profile. Venlafaxine particularly inhibits the reuptake of serotonin and in higher doses it inhibits the reuptake of norepinephrine as well. Its adverse events profile is similar to that of the selective serotonin reuptake inhibitors (SSRIs). Efficacy studies show that both compounds are effective in depressed outpatients. In depressed inpatients with psychotic features, suicidality or a longlasting episode mirtazapine is not effective and in such patients venlafaxine was not studied.
米氮平和文拉法辛是两种新型抗抑郁药，在药理作用上与其他新型抗抑郁药不同。米氮平阻断突触前α2-肾上腺素能受体，具有良好的安全性。文拉法辛特别抑制5-羟色胺的再摄取，高剂量时也抑制去甲肾上腺素的再摄取。其不良事件谱与选择性5-羟色胺再摄取抑制剂（SSRI）相似。疗效研究表明，这两种化合物对门诊抑郁症患者均有效。对于伴有精神病性特征、自杀倾向或长期发作的住院抑郁症患者，米氮平无效，且未对这类患者研究文拉法辛。
